Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists Is Awarded to Vapotherm

December 4, 2020

Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists was awarded to Vapotherm.

American Association for Respiratory Care presents the award to only six out of more than 300 manufacturers, supply organizations, and supply companies based on ranking in criteria including product quality, accessibility and helpfulness of personnel, responsiveness, service record, truth in advertising, and support of the respiratory care profession. Recipients are selected by the popular vote of AARC members in the respiratory care profession.

“We’re honored to receive the AARC Zenith Award,” said Joe Army, Vapotherm’s President and CEO. “Making our customers and their Patients a top priority is a core tenet for the Vapotherm team. This award is even more meaningful given that it is from the dedicated Respiratory Care professionals who continue to demonstrate front-line heroism during one of the most challenging years ever experienced. Thank you, Patient care colleagues, for all you and your teams are doing.”

Vapotherm increased production capacities and expanded field support teams in order to rapidly provide support during the COVID-19 pandemic. Partnering with AARC Specialty Practitioner of the Year, Felix Khusid RRT, Vapotherm launched the FELIX-1 Negative Pressure Scavenger Kit. The company also launched an open-access online learning platform, Vapotherm Academy, which has over 21,000 clinicians enrolled, in addition to its existing continuing clinical education programs.

AARC established the AARC Zenith Award in 1989 and this is the first year AARC selected Vapotherm as a recipient of the award. AARC announced the 2020 AARC Zenith Award recipients by live-stream in conjunction with the virtual 66th International Respiratory Congress on December 3rd.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy